type 1 diabetes and glp-1 receptor agonists Mechanisms by which GLP-1 agonists

Food and Drug Administration approved the medications for chronic weight management in adults with obesity or those who are overweight with at least one weight-related condition, such as high blood pressure, prediabetes or blood vessel disease

However, several significant limitations have hampered the development of PYY 3-36 as an anti-obesity drug, including its short half-life (12 min) (Addison, Minnion et al

Most individual episodes resolve within 13 days, and around 75% of users see symptoms fully clear within about 4 weeks as the body adapts

2011 Oct 11;8(3):160-71.

Your doctor can assess whether symptoms represent expected, manageable side effects or indicate a need for further investigation, dose adjustment, or alternative therapeutic approaches

However, the exact dosage and frequency will be determined by a healthcare professional based on various factors such as your medical history, current health condition, and treatment goals